Topics

Articles

While often portrayed in a negative light, it is important to find a balanced perspective on its role in the pharma sector. 

A Closer Look at PBM Spread Pricing

US biosimilars market projected to grow from less than $10 billion in 2022 to more than $100 billion by 2029.

CVS Announces Formulary Changes to Facilitate Adoption of Humira Biosimilars

Popular works in the category explore 340B guidelines, ‘smart pharma’ capabilities, and commercialization trends.

Top 3 Most-Read Supply Chain Logistics Pieces of the Year

In the face of chronic disease, DTx have the opportunity to provide a lifeline to patients. 

How Healthcare Economics Outcomes Evidence Can Pave the Way for Digital Therapeutics

Will result from Medicare reforms, despite increased drug uptake.

Continued Affordability Challenges in the Offing

While new forms of pharmacy continue to surface beyond brick-and-mortar retail, a look at what is driving this shift in perspective—and "pharmacies of the future"—is warranted.

Who Moved My Prescription?

Eli Lilly and Company's obesity drug Zepbound (tirzepatide) has a list price of $1,059.87, which is approximately 20% less than the 2.4 mg semaglutide injection indicated for weight loss.

Obesity Treatment Zepbound Now Available in United States

Investigation notes a need for greater transparency in 340B program revenue and strengthened enforcement authority for the Health Resources and Services Administration. 

Market Access and Pricing